NAD+ in Research: What the Studies Say
Here is the fact that reframes NAD+ for most people: your cells don't only use it, they take it apart. Every time a sirtuin or a PARP enzyme does its job, it cleaves a molecule of NAD+, so the whole pool has to be rebuilt continuously - the body's supply turns over several times a day. That constant teardown and resynthesis is why NAD+ keeps surfacing in aging research, and why 'nad+ benefits' ranks among the busier search phrases in this space. One thing to settle up front: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide, even though it gets shelved next to the research-peptide catalogue and occasionally mislabelled an 'nad+ peptide'. The chemistry is genuinely different, and that difference matters for how the molecule behaves.
NAD+ does three broadly different jobs inside a cell, and the aging story only makes sense once you can tell them apart.
| Role | What NAD+ does | Why it matters for aging |
|---|---|---|
| Redox and energy | Carries electrons through glycolysis and the mitochondria as the NAD+/NADH pair | Sets the ceiling on ATP production |
| DNA repair | Consumed by PARP enzymes that tag and repair damaged DNA | Rising DNA damage drains the pool with age |
| Sirtuin signalling | Fuels the NAD+-dependent enzymes that regulate genes and metabolism | Low NAD+ means quieter sirtuins |
The redox job: electron traffic
In its most basic role, NAD+ is an electron shuttle. It accepts a pair of electrons stripped from glucose and fatty acids, becomes NADH, and delivers that cargo to Complex I at the start of the mitochondrial electron transport chain, where it helps drive ATP production. The ratio of NAD+ to NADH is one of the cell's core readouts of its own energy state - a running tally of supply against demand. Nothing exotic here; this is textbook metabolism, happening billions of times a second in every tissue you have.
The demanding customers: PARPs and sirtuins
The interesting part for longevity is the enzymes that consume NAD+ outright rather than recycling it. PARPs fire whenever DNA breaks, using NAD+ as raw material to flag the damage for repair. Sirtuins - a family tied to metabolic regulation, stress resistance, and gene silencing - also need NAD+ to run, snipping it apart with every reaction. Both are doing useful work. Both drain the pool. As DNA damage accumulates and inflammation climbs with age, demand rises while supply slips, and that mismatch is where a lot of the research attention sits.
Why NAD+ falls with age
Measured NAD+ drops substantially between youth and old age across several tissues. The decline isn't one problem but a squeeze from both ends: PARP demand rises with accumulating DNA damage, an enzyme called CD38 climbs alongside age-related inflammation and eats through NAD+ and its precursors, and the salvage pathway that regenerates NAD+ from nicotinamide gets less efficient. That is the gap the research is trying to close - not adding something new to biology, but restoring a level the body used to hold on its own. NAD is supplied directly for that research, alongside precursor molecules that feed the same salvage pathway.
The enzyme angle: 5-Amino-1MQ and NNMT
There's a sideways route into NAD+ metabolism worth knowing about. NNMT (nicotinamide N-methyltransferase) methylates nicotinamide - a direct NAD+ precursor - and marks it for disposal, spending a methyl group from SAM in the process. When NNMT runs hot, it siphons precursor away from NAD+ synthesis. 5-Amino-1MQ is a small molecule that inhibits NNMT, which is why it turns up in metabolic and NAD-adjacent research; most of its study so far centres on adipocyte metabolism and energy expenditure. I put it head to head with a mitochondrial peptide in MOTS-c versus 5-Amino-1MQ, and it also features in the broader longevity research guide.
What the NAD+ research does and doesn't show
The mechanism is solid - the decline is real, the enzymes are well characterized, the biochemistry isn't in dispute. Does topping NAD+ back up in a living organism reliably slow any part of aging? That is the open question, and the honest read is that the human evidence is early and mixed: promising cell and animal data, smaller and less consistent human trials. If you're sourcing for lab work, the full range including NAD is on our research catalogue. Treat it as an active research question, not a finished one.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.